

G. Alzeeb, C. Gongora, C. Richard, R. Boidot, T. Fortin, Y. Wang, A. Bessede, B. Pinteur, L. Chalus, C. Tortorelli, P. Bravetti, F. Ghiringhelli ¹Brenus Pharma, Lyon, France,²INSERM U1194, Montpellier, France,³CNRS 6302, Dijon, France,⁵Inovotion, La Tronche, France,⁶Explicyte, Bordeaux, France,⁷Inserm 1231, Dijon, France

INTRODUCTION AND BACKGROUND

- of relapse. The lead vaccine candidate, STC-1010 is targeting CRC.






cannot be calculated.

EX-VIVO IMMUNE RESPONSE ACTIVATION AND INDUCTION OF TUMOR KILLING

Fig. 8 Illustrating method of Ex-vivo model

Immune response activation and induction of CRC human cell lines Killing

1. Ex-vivo monocyte differenciation into Dendritic Cells



5003 - EFFICACY OF THE STC-1010 A NEW ALLOGENEIC CANCER VACCINE IN DIFFERENT COLORECTAL CANCER MODELS

• 143 Cancer-Related Protein (CRP) from the Atlas proteins' database were identified in 4 batches of STC-1010 including CRC-specific proteins' database were identified in 4 batches of STC-1010 including CRC-specific proteins' database were identified in 4 batches of STC-1010 including CRC-specific proteins and Tumor-Associated Antigens linked to tumor plasticity and resistances. (Fig. 4)




Fig 9. Significant anti-tumor effect of STC-1010 against different CRC cell lines Tested on 6 donors for HCT116 (+50% apotosis) and on 4 donros for SW620 (+30% apotosis)

STC-1010 INDUCES MASSIVE APOTOSIS OF HUMAN CRC CELL LINES (ALLOGENEIC MODEL)

value=0,0368).

I/II clinical trial for metastatic CRC patients.

TRANSCRIPTOMIC SIGNATURE TO IDENTIFY AND QUANTIFY DS IN DRUG PRODUCT							
	HCT-116		HT29		LoVo		
%	DSA	DSB	DSA	DSB	DSA	DSB	
STC-1010	17,2	19,2	17,4	13,7	17,5	15,0	

MMUNE CHECKPOINT IODEL	
wironment (TME)	 In vivo models confirm the efficacy of the STC platform within its different production steps, highlighting that a three-cell line approach (mSTC-1010) improves survival of treated tumor-baring mice over single-cell line vaccine (<i>Fig. 6</i>), and haptenation significantly enhances stressed cells vaccine anti-tumor efficacy (<i>Fig. 5</i>).
	 STC Platform also demonstrates significant anti-tumor activity in immune checkpoint resistant CRC in vivo model (Fig. 7)
40 45 50 Aring mice bearing MC38- anti-PD-1 Log-rank Mantel-Cox test, p-	

• Ex-vivo model, from different donors, mimicking human conditions confirms a significant antitumor efficacy of human STC-1010 against CRC cell lines in an allogeneic model demonstrating a powerfull immune induction. (Fig. 8,9)

• STC-1010 induces a robust anti-tumor efficacy performed via CD8+ LT apotosis induction against CRC tumor with a perfect **batch to batch reproducibility** (Fig. 10)

Fig 10. Apotosis index of HCT116 tumor cells induced by STC-1010 (RD1, RD2, RD3) vs Control at 72h



• STC vaccine was tested on different models (in-vivo, ex-vivo) and confirms that the 3 cell lines, stimulated and haptenized vaccine is the best option

• A robust STC batch to batch reproducibility has been validated with multi-omic characterization and with ex-vivo induction of tumor apoptosis. • The good tolerability and reproducible efficiency of the STC-1010 vaccine in these different pre-clinical models allow to plan a first-in-human phase



